How Did Biome Australia Achieve Record $18.4M Sales in FY25?
Biome Australia Limited has confirmed its record FY25 sales revenue of approximately $18.4 million, marking a 41% increase year-on-year, while affirming full compliance with ASX continuous disclosure rules.
- Unaudited FY25 sales revenue of ~$18.4 million, up 41% from FY24
- Strongest quarter to date in Q4 FY25 with sales exceeding $5 million
- June 2025 monthly sales hit a record ~$2.1 million, a 50% increase
- Company confirms timely disclosure and compliance with ASX Listing Rules
- No material information withheld prior to public announcement
Record Sales Growth Confirmed
Biome Australia Limited (ASX, BIO) has officially confirmed its unaudited full-year sales revenue for the financial year ended 30 June 2025 at approximately $18.4 million. This represents a robust 41% increase compared to the previous corresponding period's $13.01 million in FY24, underscoring the company’s accelerating growth trajectory within the biotechnology sector.
The company also highlighted that its fourth quarter of FY25 was the strongest on record, with sales revenue exceeding $5 million; a 33% uplift over the same quarter last year. June 2025 alone saw record monthly sales of around $2.1 million, marking a 50% increase versus the prior corresponding period, signaling strong momentum heading into the new financial year.
Transparency and Compliance with ASX Rules
In response to inquiries from ASX Limited, Biome Australia detailed the timing and process behind finalizing these sales figures. The company confirmed it became aware of the final sales data at 5, 41pm EST on 30 June 2025, after the close of business, following a thorough internal review and approval by the Board within hours. The announcement was then promptly released on 1 July 2025 before market open.
Importantly, Biome Australia affirmed that no material price-sensitive information was withheld prior to the announcement and that it was not relying on any exceptions under ASX Listing Rule 3.1A to delay disclosure. The company’s Cleansing Notice issued on 30 June 2025 was consistent with market expectations, and the final sales figures fell within the anticipated range, ensuring transparency and adherence to continuous disclosure obligations.
Market Expectations and Analyst Forecasts
Prior to the announcement, Biome Australia had reported steady quarterly sales growth and had communicated positive expectations for Q4 as its historically strongest period. Analyst forecasts, including those from Bell Potter, had projected full-year revenue around $18.9 million, closely aligning with the company’s final reported figure. This alignment suggests that the market had already priced in much of the anticipated growth, reducing the risk of unexpected volatility upon release.
While the sales figures are currently unaudited, they provide a strong indication of Biome Australia’s operational performance and growth prospects. Investors will be keenly awaiting the audited financial statements for further confirmation and insights into profitability and cost structures.
Looking Ahead
Biome Australia’s record sales performance in FY25 positions the company well for continued expansion in the competitive biotechnology landscape. The company’s clear communication and compliance with ASX disclosure requirements also reinforce investor confidence in its governance and transparency practices.
Bottom Line?
With record sales confirmed and compliance assured, Biome Australia sets the stage for a closely watched FY25 financial report.
Questions in the middle?
- How will Biome Australia’s profitability and margins evolve alongside its strong sales growth?
- What impact will these sales figures have on Biome’s valuation and investor sentiment?
- Can Biome sustain or accelerate this growth trajectory in FY26 amid sector competition?